

# A Personalized Blood Test to Help You and Your Health Care Provider Find the Right Rheumatoid Arthritis Medication Sooner


Rheumatoid arthritis (RA) **affects everyone differently**, therefore, each person should have a unique treatment approach.

## There's a new way to select your medication for RA

RA is complex and affects every person differently. If left untreated, RA inflammation can damage multiple organs and increase your risk of heart disease.<sup>1</sup>

## The goal of treatment is to protect you from the potential damage caused by inflammation.

There are many medications used to treat RA. However, until PrismRA, health care providers did not have a tool to help make more informed treatment decisions.



**prism/RA**

**PrismRA is a personalized test** based on your unique biology, that can help guide your provider when considering changes to your treatment.

## Finding the right RA treatment for you

If your RA is flaring up and you're feeling unwell, your health care provider may suggest starting or increasing dosage of a medication called TNF inhibitor (TNFi) therapy.

TNFi therapies are commonly prescribed as a first-line biologic therapy.<sup>2</sup> While this drug type works for some, it is not a one-size-fits-all treatment. Every person is unique and may respond to medications differently.

With TNFi therapies, and the many other available medications, it can be hard to know which one is best for you.

Using the PrismRA result, your provider may decide to change the dosage of your current medication or start you on a new medication as the best approach to get your RA under control.

**prism/RA**

**MOLECULAR SIGNATURE TEST**  
Sample Patient Report

HEALTHCARE PROVIDER	CLINIC	PATIENT
<b>Name:</b> Rachel Smith <b>Requisition No.:</b> 00000000001 <b>Collection Date:</b> 02/05/2025 <b>Specimen Received:</b> 02/05/2025 10:30:17 <b>Report Date:</b> 02/09/2025	<b>Clinic Name:</b> Community Rheumatology Clinic <b>Address:</b> 34 Main St. Ste 200 Boston, MA 02110 <b>Phone:</b> (617) 111-1234 <b>Fax:</b> (617) 222-5678	<b>Name:</b> Diana Johnson <b>DOB:</b> 1/23/1969 <b>Sex:</b> F <b>Weight:</b> 150.00 lbs <b>Height:</b> 5'07" 100" <b>Patient Global Assessment:</b> 50

**PrismRA RESULT**

PrismRA TNFi Result:	Interpretative Criteria:
<b>TNFi Inadequate Response Signature Not Detected</b>  This patient has a PrismRA Score of <b>9.2</b>	<b>Patient may be likely to respond to a TNFi</b>  <b>&lt;10.6:</b> Patient does not have a detectable molecular signature of inadequate response to TNFi therapies

**PrismRA SCORE INTERPRETATION**

A patient with a PrismRA Score <10.6 does not have a detectable molecular signature of inadequate response to TNFi therapies. The PrismRA result is reported on a continuous 1-25 scale. The higher the score, the more likely the patient will have an inadequate response to TNFi therapies; the lower the score, the less likely the patient will have an inadequate response to TNFi therapies.

**TEST DESCRIPTION**

PrismRA PrismRA is a molecular signature response classifier (MSRC) that uses gene expression features, clinical features, and anti-cyclic citrullinated protein (anti-CCP) antibody to detect a signature of non-response to tumor necrosis factor- $\alpha$  inhibitors (TNFi) for patients with rheumatoid arthritis. PrismRA predicts the patient's likelihood of inadequately responding to all TNFi therapies.

Total RNA was extracted from PAXgene® whole blood sample and sequenced at Ambry Genetics. The extracted RNA samples were quantified and had their RNA integrity determined. RNA was sheared, cDNA converted, and library prepared via hybrid capture. After library amplification, samples were sequenced on a NovaSeq 6000 (Illumina). Anti-CCP antibody measurements were performed at Scipher using in vitro semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides in human serum. Final algorithmic analysis was performed at Scipher with PrismRA pipeline v1.02. The PrismRA result is reported on a continuous 1 to 25 scale. The higher the score, the more likely the patient will have an inadequate response to TNFi therapies; the lower the score, the less likely the patient will have an inadequate response to TNFi therapies. However, a low score does not ensure a positive response to TNFi therapies. Response is defined as achieving ACR50 at 6 months.

**COMMENTS**

The PrismRA result is intended for informational purposes only and does not constitute a recommendation. Medical management decisions should be made by a healthcare provider with the full medical history and clinical assessment of the patient. The PrismRA test is intended for clinical use. This test was developed and its performance characteristics determined by Scipher Bioscience, Inc. No third-party approval is required for this test and drug administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical testing. For full test specifications and related publications please visit [www.PrismRA.com](https://www.PrismRA.com).

**Laboratory CLIA Number:** 342807076  
**Laboratory CAP Number:** 0228108  
**Laboratory Director:** Sarah Reynolds, PhD, FACMG

Scipher Bioscience

Early diagnosis and treatment in RA is associated with improved outcomes.<sup>7</sup> Maximize your window of opportunity and see if PrismRA can help your health care provider find the right treatment for you.

## PrismRA uses your unique biology

PrismRA is the first and only available blood test that analyzes your unique biology to tell you if TNFi therapies such as infliximab, adalimumab, or etanercept, are less likely to work for you.<sup>3,4</sup>

## Getting on the correct therapy sooner helps:



decrease  
pain<sup>5</sup>




reduce your  
risk of joint  
damage<sup>5</sup>



improve  
your quality  
of life<sup>5</sup>

Patient's with moderate to severely active disease who were prescribed treatment based on their PrismRA result had clinical improvements that were more than 3 times higher than those whose treatment did not align with test results.<sup>6</sup>



## Patient Billing

We are committed to making testing more accessible and affordable. Our team will work directly with your insurance provider and health care provider to try to obtain coverage while minimizing any financial burden.



### Patient-Friendly Billing Policy

- Scipher is a Medicare participating provider and is contracted with a number of health insurance plans.
- PrismRA is covered by both Medicare and Medicare Advantage.
- Please contact the your health plan directly about your individual benefits.



### Affordable Payment Plans

- We offer payment plans and financial assistance to those who qualify to ensure all patients have equal access to PrismRA.

**Ask your health care provider**  
if the PrismRA Test can help  
guide your medical care.

Call our Billing Specialists at  
**(855) 724-7437 option #1** or  
email **Billing@Scipher.com**.

Call our Client Services team  
at **(855) 724-7437** or email  
**Support@Scipher.com**.

1. Arthritis Foundation: Rheumatoid Arthritis and Heart Disease. [www.arthritis.org/health-wellness/about-arthritis/related-conditions/other-diseases/rheumatoid-arthritis-heart-disease](http://www.arthritis.org/health-wellness/about-arthritis/related-conditions/other-diseases/rheumatoid-arthritis-heart-disease). Accessed 4/22/22. 2. Jin Y, et al. *Arthritis Res Ther*. 2017;19(1):159. Published 2017 Jul 5. doi:10.1186/s13075-017-1366-1. 3. Jones A, et al. *Expert Rev Mol Diagn*. 2021;21(11):1235-1243. doi:10.1080/14737159.2021.2000394. 4. Cohen S, et al. *Rheumatol Ther*. 2021;8(3):1159-1176. doi:10.1007/s40744-021-00330-y. 5. Creaky Joints: RA Testing Patient Guideline. [https://creakyjoints.org/www/wp-content/uploads/CreakyJoints\\_RA\\_Testing\\_Patient\\_Guideline.pdf](https://creakyjoints.org/www/wp-content/uploads/CreakyJoints_RA_Testing_Patient_Guideline.pdf). Accessed 6/1/22. 6. Strand V, et al. *Expert Rev Mol Diagn*. 2022;22(1):101-109. doi:10.1080/14737159.2022.2020648. 7. Fraenkel L, et al. 2021. *Arthritis Care Res (Hoboken)*. 2021;73(7):924-939. doi:10.1002/acr.24596.

Scipher Medicine, complies with the Section 1557 Nondiscrimination Notice and does not discriminate on the basis of race, color, religion, sex, marital status, sexual orientation, gender identity or expression, English language proficiency, national origin, age, disability, veteran status or any other status protected by law. ATTENTION: If the primary language you speak is other than English, language assistance services, free of charge, are available to you. Call 1-855-724-7437.